Author

Flavio Caprioli

EXPLORING THE TRASCRIPTOMIC UNDERPINNING THE EFFECT OF BIOLOGICAL THERAPIES ON SARS-COV-2 SUSCEPTIBILITY IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS
EXPLORING THE TRASCRIPTOMIC UNDERPINNING THE EFFECT OF BIOLOGICAL THERAPIES ON SARS-COV-2 SUSCEPTIBILITY IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS

Flavio Caprioli  et al.

SERUM PROTEOMICS AND METABOLOMICS STUDY ON SUSCEPTIBILITY TO SARS-COV-2 INFECTION IN IBD PATIENTS
SERUM PROTEOMICS AND METABOLOMICS STUDY ON SUSCEPTIBILITY TO SARS-COV-2 INFECTION IN IBD PATIENTS

Flavio Caprioli  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Flavio Caprioli  et al.

VACCINATION STATUS AND ATTITUDES TOWARDS VACCINES IN A NATIONAL COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES
VACCINATION STATUS AND ATTITUDES TOWARDS VACCINES IN A NATIONAL COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Flavio Caprioli  et al.

BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS
BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS

Flavio Caprioli  et al.

PORPHYROMONAS GINGIVALIS SUPPORTS COLON CANCER PROGRESSION BY SWITCHING INKT CELL FUNCTIONS TOWARDS A PRO-TUMORIGENIC PHENOTYPE
PORPHYROMONAS GINGIVALIS SUPPORTS COLON CANCER PROGRESSION BY SWITCHING INKT CELL FUNCTIONS TOWARDS A PRO-TUMORIGENIC PHENOTYPE

Flavio Caprioli  et al.

TELEMONITORING IBD WITH THE APP CARE4TODAY IBD: A REAL-LIFE CASE-CONTROL STUDY
TELEMONITORING IBD WITH THE APP CARE4TODAY IBD: A REAL-LIFE CASE-CONTROL STUDY

Flavio Caprioli  et al.

INKT CELL-NEUTROPHIL CROSSTALK PROMOTES COLORECTAL CANCER PATHOGENESIS
INKT CELL-NEUTROPHIL CROSSTALK PROMOTES COLORECTAL CANCER PATHOGENESIS

Flavio Caprioli  et al.

MAINTENANCE OF CLINICAL BIOCHEMICAL AND TRANSMURAL REMISSION IN IBD PATIENTS SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB
MAINTENANCE OF CLINICAL BIOCHEMICAL AND TRANSMURAL REMISSION IN IBD PATIENTS SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB

Flavio Caprioli  et al.

ACCURACY OF INTESTINAL ULTRASOUND IN DISCRIMINATING BETWEEN IRRITABLE BOWEL SYNDROME AND CROHN’S DISEASE WITH SIMILAR CLINICAL PRESENTATION
ACCURACY OF INTESTINAL ULTRASOUND IN DISCRIMINATING BETWEEN IRRITABLE BOWEL SYNDROME AND CROHN’S DISEASE WITH SIMILAR CLINICAL PRESENTATION

Flavio Caprioli  et al.

EFFECT OF TOFACITINIB ON COLECTOMY RISK IN ANTI TNF-ALFA REFRACTORY ULCERATIVE COLITIS
EFFECT OF TOFACITINIB ON COLECTOMY RISK IN ANTI TNF-ALFA REFRACTORY ULCERATIVE COLITIS

Flavio Caprioli  et al.

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB FORMULATION DETERMINES A REDUCTION OF ANTIDRUG ANTIBODY LEVELS
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB FORMULATION DETERMINES A REDUCTION OF ANTIDRUG ANTIBODY LEVELS

Flavio Caprioli  et al.

THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB
THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB

Flavio Caprioli  et al.

REDUCED HUMORAL RESPONSE TO TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE-IBD, AN IG-IBD STUDY
REDUCED HUMORAL RESPONSE TO TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE-IBD, AN IG-IBD STUDY

Flavio Caprioli  et al.

Item 1 - 14 / 14
1